Out of 2 analysts covering Repros Therapeutics (NASDAQ:RPRX), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Repros Therapeutics was the topic in 4 analyst reports since August 20, 2015 according to StockzIntelligence Inc. Below is a list of Repros Therapeutics Inc (NASDAQ:RPRX) latest ratings and price target changes.
30/10/2015 Broker: Ladenburg Thalmann Old Rating: Buy New Rating: Neutral Downgrade
30/10/2015 Broker: Bank of America Old Rating: Neutral New Rating: Underperform Downgrade
30/10/2015 Broker: Brean Capital Old Rating: Buy New Rating: Hold Downgrade
20/08/2015 Broker: Zacks Old Rating: buy New Rating: hold New Target: $8.75 Upgrade
About 72,705 shares traded hands. Repros Therapeutics Inc (NASDAQ:RPRX) has declined 87.91% since July 15, 2015 and is downtrending. It has underperformed by 78.91% the S&P500.
Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has a market cap of $22.04 million. The Company’s product candidates include Androxal and Proellex. It currently has negative earnings. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.
The institutional sentiment decreased to 0.54 in Q3 2015. Its down 0.20, from 0.74 in 2015Q2. The ratio dropped, as 22 funds sold all Repros Therapeutics Inc shares owned while 17 reduced positions. 12 funds bought stakes while 9 increased positions. They now own 12.80 million shares or 11.64% less from 14.48 million shares in 2015Q2.
Sarissa Capital Management Lp holds 2.08% of its portfolio in Repros Therapeutics Inc for 1.13 million shares. Destrier Capital Management Llc owns 329,030 shares or 0.72% of their US portfolio. Moreover, Rtw Investments Llc has 0.54% invested in the company for 229,364 shares. The New York-based General American Investors Co Inc has invested 0.34% in the stock. Cqs Cayman Lp, a Cayman Islands-based fund reported 240,000 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.